Abstract
The purpose of this study was to estimate the diagnostic accuracy of anti-carbamylated protein (anti-CarP) antibodies in rheumatoid arthritis. We searched the PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus databases for studies published before January 1, 2019. Two investigators independently evaluated studies to determine their inclusion in the analysis, assess their quality, and extract the relevant data. The articles were assessed with the Quality Assessment of Diagnostic Accuracy Studies tool, and a bivariate mixed effects model was used to estimate the diagnostic indexes across studies. We included 16 published studies in this meta-analysis. The pooled sensitivity and specificity of anti-CarP were 43.1% and 94.4%, respectively. The area under the summary receiver operator characteristic curve was 0.55. The specificity estimates were highly heterogeneous, which could be partly explained by the higher specificity in the healthy control group (43.0%, 96.8%) than in the other disease group (43.4%, 89.8%). Anti-CarP antibodies have a relatively low sensitivity and high specificity for rheumatoid arthritis. However, the specificity was lower in the other disease subgroups than in the healthy controls.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.